A Medical Monoculture or the Blooming of 1000 Flowers? Identifying and mitigating barriers to accessing psychedelic medicines post market authorisation.

A number of psychedelic medicines are in late stage clinical trials leading many to ask the question of what happens when these drugs reach market. Who will get access and how? Are our current infrastructures adequately prepared to deliver psychedelic medicines? By reflecting on the nature of these interventions, scrutinising current routes of access to mental health treatments,  and by taking lessons from cannabis and ketamine, this talk will explore a provisional model of access which reduces risks and maximises benefits. Two interventions required to achieve it will be presented.

‍

Biography: Timmy Davis is director of psychedelic policy and regulation at the Centre for Evidence Based Drug Policy (CEBDP), co-founder and policy director at the Psilocybin Access Rights (PAR) campaign, the founder of The Psychedelic Experience Clinic and a trainee at the Site for Contemporary Psychoanalysis.

‍